The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS ...